Results 11 to 20 of about 10,221 (208)
The pituitary TGFb1 system as a novel target for the treatment of resistant prolactinomas [PDF]
, 2016 Prolactinomas are the most frequently observed pituitary adenomas and most of themrespond well to conventional treatment with dopamine agonists (DAs).
Camilletti, María Andrea +3 more
core +2 more sources
Sex differences in the pituitary TGFβ1 system: the role of TGFβ1 in prolactinoma development [PDF]
, 2019 Prolactinomas are the most frequent functioning pituitary adenomas, and sex differences in tumor size, behavior and incidence have been described. These differences have been associated with earlier diagnosis in woman, as well as with serum estradiol ...
Abeledo Machado, Alejandra Inés +6 more
core +1 more source
A macroprolactinoma becoming resistant to cabergoline and developing atypical pathology [PDF]
, 2016 Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. They can be classified according to pathological, radiological or clinical behaviour as typical, atypical or carcinomas, invasive or noninvasive, and ...
Ansorge, Olaf +6 more
core +3 more sources
Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro [PDF]
, 2001 Angiogenesis, the formation of a new blood supply, is an essential step in tumorigenesis. Although vascular endothelial growth factor (VEGF) is known to be a very potent angiogenic factor in most solid tumors, little is known about its production and ...
Gloddek, Jutta +7 more
core +1 more source
Developmental and functional effects of steroid hormones on the neuroendocrine axis and spinal cord [PDF]
, 2016 This review highlights the principal effects of steroid hormones at central and peripheral levels in the neuroendocrine axis. The data discussed highlight the principal role of oestrogens and testosterone in hormonal programming in relation to sexual ...
Gonzalez Deniselle, Maria Claudia +4 more
core +2 more sources
BMC Endocrine Disorders, 2022 Background Recently, side effects from Dopamine Receptor Agonist Drugs (DAs) in treating pituitary prolactinoma have raised widespread concern. This study explores the incidence and influencing factors of DAs-related side effects in Chinese prolactinoma ...
Xiaoan Ke +7 more
doaj +1 more source
Cabergoline Treatment in Invasive Giant Prolactinoma
Clinical Medicine Insights: Case Reports, 2014 Patients with invasive giant prolactinoma suffer from a constellation of symptoms including headache, blurred vision, lethargy, and sexual dysfunction. Cabergoline, a potent dopamine agonist, is a known medication prescribed for the treatment of invasive
Sadeem Alsubaie, Mussa H. Almalki
doaj +1 more source
Journal of International Medical Research, 2019 Objectives To investigate the expression levels of aromatase cytochrome P450 enzyme (P450AROM) and related molecules—estrogen receptor-beta (ER-β), Ki-67, and p53—in prolactinoma tumor tissue from pre- and post-menopausal women, and to determine the ...
Yin-Xia Su +9 more
doaj +1 more source
Prolactinoma presenting as chronic anaemia with osteoporosis: a case report
Journal of Medical Case Reports, 2010 Introduction Unexplained anaemia is a rare mode of presentation for prolactinoma. We describe a case of a man, with chronic anaemia ascribed to old age.
Hanley John P, MacLean Fergus R
doaj +1 more source
Indian Journal of Endocrinology and Metabolism, 2021 Cabergoline has long been used in the medical management of prolactin-secreting pituitary adenomas. However, there is contradicting and inadequate evidence on the efficacy of cabergoline in achieving radiological and biochemical remission in prolactinoma.
Rakesh Mishra +5 more
doaj +1 more source